Other formats:
BibTeX
LaTeX
RIS
@article{2291837, author = {Aswad, Mohamed Hussam and Kissová, Jarmila and Ovesná, Petra and Říhová, Lucie and Penka, Miroslav}, article_location = {AMSTERDAM}, article_number = {4}, doi = {http://dx.doi.org/10.3233/CH-221678}, keywords = {Essential thrombocythemia; thrombosis; risk factor; JAK2V617F mutation; extracellular vesicles}, language = {eng}, issn = {1386-0291}, journal = {CLINICAL HEMORHEOLOGY AND MICROCIRCULATION}, title = {JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia}, url = {https://content.iospress.com/articles/clinical-hemorheology-and-microcirculation/ch221678}, volume = {84}, year = {2023} }
TY - JOUR ID - 2291837 AU - Aswad, Mohamed Hussam - Kissová, Jarmila - Ovesná, Petra - Říhová, Lucie - Penka, Miroslav PY - 2023 TI - JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia JF - CLINICAL HEMORHEOLOGY AND MICROCIRCULATION VL - 84 IS - 4 SP - 359-368 EP - 359-368 PB - IOS PRESS SN - 13860291 KW - Essential thrombocythemia KW - thrombosis KW - risk factor KW - JAK2V617F mutation KW - extracellular vesicles UR - https://content.iospress.com/articles/clinical-hemorheology-and-microcirculation/ch221678 N2 - The clinical course of essential thrombocythemia (ET) is complicated with thrombosis which significantly impacts patients’ mortality. Studies have identified JAK2V617F mutation as an independent risk factor for thrombosis. Circulating extracellular vesicles (EVs) were evaluated in several studies regarding myeloproliferative neoplasms and thrombosis as potential biomarkers. The present study investigates the relationship between JAK2V617F mutation and EVs levels in 119 ET patients. Our analyses revealed that JAK2V617F-positive patients are at a significantly increased risk of thrombosis within five years before the ET diagnosis (hazard ratio [95% CI]: 11.9 [1.7–83.7], P = 0.013), and that JAK2V617F mutation is an independent risk factor for thrombosis at ET diagnosis or during the follow-up (hazard ratio [95% CI]: 3.56 [1.47–8.62], P = 0.005). ET patients have higher levels of platelet-EVs, erythrocyte-EVs and procoagulant activity of EVs than the healthy population. Absolute and relative counts of platelet-EVs are increased in the presence of JAK2V617F mutation (P = 0.018, P = 0.024, respectively). In conclusion, our results support the role of JAK2V617F mutation in the pathogenesis of thrombosis in essential thrombocythemia through enhancing platelet activation. ER -
ASWAD, Mohamed Hussam, Jarmila KISSOVÁ, Petra OVESNÁ, Lucie ŘÍHOVÁ and Miroslav PENKA. JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia. \textit{CLINICAL HEMORHEOLOGY AND MICROCIRCULATION}. AMSTERDAM: IOS PRESS, 2023, vol.~84, No~4, p.~359-368. ISSN~1386-0291. Available from: https://dx.doi.org/10.3233/CH-221678.
|